At a glance
ClinicalIndex Comparison RecordN/ACompleted· 930 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Acute Kidney Injury Neutrophil Gelatinase-Associated Lipocalin (N-GAL) Evaluation of Symptomatic Heart Failure Study (AKINESIS)
In Brief
An observational study for Acute Decompensated Heart Failure and Acute Kidney Injury. Completed, enrolled 930 participants across 13 sites in 7 countries.
Detailed Summary
AKINESIS is a clinical study to assess the utility of blood and urine NGAL tests in predicting worsening kidney function in patients who present with acute heart failure (AHF) and who are treated with diuretics. It is believed that rising NGAL levels in the blood and/or urine can predict acute kidney injury. It is also believed that patients who are admitted to the hospital with high NGAL levels in the blood/urine will have poorer outcomes.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesGreece, Ireland, Italy, Netherlands, Spain, Switzerland, United States
CollaboratorsAbbott Diagnostics Division, Alere, Inc.
Timeline
N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartDec 2010
First PostedFeb 2011
Primary CompletionOct 2013
Study CompletionJun 2015
TodayJul 2026
First PostedFeb 9, 2011
Enrollment StartDec 1, 2010
Primary CompletionOct 1, 2013
Study CompletionJun 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 15.4 years ago